NDNika N. Danial

Nika N. Danial

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nika N. Danial has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MYC primes a paralog synthetic lethality involving the mitochondrial translocase subunits TIMM17A and TIMM17B and N-Acetylaspartate

    by Sydney M. Moyer, Nina Ilic, Sydney Gang, Lucas Dailey, Sehyun Oh, Jasmine Stavridi, Gaia Taig, Kathia E. Rodarte, Joseph D. DeAngelo, Andrea Jiang, et al.

    To identify the genes and pathways required for the survival of MYC -amplified cancers, we engineered an isogenic cell system in which transformation is driven by oncogenic MYC . Using a genome-scale CRISPR-Cas9 library, we identified the mitochondrial membrane translocase TIMM17A as uniquely essential for the survival of MYC-transformed cells. This dependency arises from MYC-driven suppression of TIMM17B , the paralog of TIMM17A . TIMM17A/B is an essential component of the TIM23 mitochondrial protein import complex, and the MYC-induced suppression of TIMM17B creates a strong dependency on TIMM17A . N-acetylaspartate supplementation rescued TIMM17A dependency in MYC -amplified cell lines, highlighting the unique and crucial role of this metabolite in the cell fitness of MYC -amplified cancers. These observations identify a paralog dependency required for the survival of a subset of MYC-driven cancers.

  • Multiple anti-tumor programs are activated by blocking BAD phosphorylation

    by John Maringa Githaka, Raven Kirschenman, Namrata Patel, Namita Tripathi, Joy Wang, Laiji Li, Heather Muranyi, Leila Pirayeshfard, Rachel Montpetit, Darryl D. Glubrecht, et al.

    The Bcl-2 family member BAD is a candidate disease modulator because it stimulates apoptosis in a cell context basis and inhibits cell migration during normal mammary gland morphogenesis. This activity depends on 3 key regulatory serines (S75, 99, 118) in the unphosphorylated state. Given that developmental programs are often hijacked in cancer, we hypothesized that BAD would impede breast cancer progression. We generated breast cancer mouse models representing loss-of-function or phosphorylation deficient mutations (PyMT-Bad−/− and PyMT-Bad3SA/3SA, respectively). Preventing BAD phosphorylation significantly decreased breast cancer progression and metastasis. The knock-out phenocopied the control PyMT-Bad+/+ suggesting that phosphorylated BAD protein was inert. Thus, the BAD3SA mutation unmasked latent anti-tumor activity. Indeed, transcriptomics showed PyMT-Bad3SA/3SA activated multiple anti-tumor programs including apoptosis, inflammation, cellular differentiation, and diminished cell migration. This anti-tumor effect associated with clinical survival of breast cancer patients whose tumors had high levels of unphosphorylated BAD. Kinase screens identified ERK as the major BAD kinase in breast cells, and ERK inhibition impeded tumoroid invasion. Our data suggest that unphosphorylated BAD modulates anti-tumor pathways that contribute to excellent patient prognosis. Thus, targeting ERK to dephosphorylate BAD may be an exciting therapeutic opportunity in the future.


  • Open Access

    Mitochondrial morphology controls fatty acid utilization by changing CPT1 sensitivity to malonyl‐CoA

    by Jennifer Ngo, Dong Wook Choi, Illana A Stanley, Linsey Stiles, Anthony J A Molina, Pei‐Hsuan Chen, Ana Lako, Isabelle Chiao Han Sung, Rishov Goswami, Min‐Young Kim, et al.

    Changes in mitochondrial morphology are associated with nutrient utilization, but the precise causalities and the underlying mechanisms remain unknown. Here, using cellular models representing a wide variety of mitochondrial shapes, we show a strong linear correlation between mitochondrial fragmentation and increased fatty acid oxidation (FAO) rates. Forced mitochondrial elongation following MFN2 over‐expression or DRP1 depletion diminishes FAO, while forced fragmentation upon knockdown or knockout of MFN2 augments FAO as evident from respirometry and metabolic tracing. Remarkably, the genetic induction of fragmentation phenocopies distinct cell type‐specific biological functions of enhanced FAO. These include stimulation of gluconeogenesis in hepatocytes, induction of insulin secretion in islet β‐cells exposed to fatty acids, and survival of FAO‐dependent lymphoma subtypes. We find that fragmentation increases long‐chain but not short‐chain FAO, identifying carnitine O‐palmitoyltransferase 1 (CPT1) as the downstream effector of mitochondrial morphology in regulation of FAO. Mechanistically, we determined that fragmentation reduces malonyl‐CoA inhibition of CPT1, while elongation increases CPT1 sensitivity to malonyl‐CoA inhibition. Overall, these findings underscore a physiologic role for fragmentation as a mechanism whereby cellular fuel preference and FAO capacity are determined.


  • Open Access

    MCL-1 is a master regulator of cancer dependency on fatty acid oxidation

    by Michelle S. Prew, Utsarga Adhikary, Dong Wook Choi, Erika P. Portero, Joao A. Paulo, Pruthvi Gowda, Amit Budhraja, Joseph T. Opferman, Steven P. Gygi, Nika N. Danial, et al.


  • Open Access

    Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2–dependent glutaminolysis pathway

    by Peng Wei, Alex J. Bott, Ahmad A. Cluntun, Jeffrey T. Morgan, Corey N. Cunningham, John C. Schell, Yeyun Ouyang, Scott B. Ficarro, Jarrod A. Marto, Nika N. Danial, et al.

    The fate of pyruvate is a defining feature in many cell types. One major fate is mitochondrial entry via the mitochondrial pyruvate carrier (MPC). We found that diffuse large B cell lymphomas (DLBCLs) consume mitochondrial pyruvate via glutamate-pyruvate transaminase 2 to enable α-ketoglutarate production as part of glutaminolysis. This led us to discover that glutamine exceeds pyruvate as a carbon source for the tricarboxylic acid cycle in DLBCLs. As a result, MPC inhibition led to decreased glutaminolysis in DLBCLs, opposite to previous observations in other cell types. We also found that MPC inhibition or genetic depletion decreased DLBCL proliferation in an extracellular matrix (ECM)–like environment and xenografts, but not in a suspension environment. Moreover, the metabolic profile of DLBCL cells in ECM is markedly different from cells in a suspension environment. Thus, we conclude that the synergistic consumption and assimilation of glutamine and pyruvate enables DLBCL proliferation in an extracellular environment-dependent manner.


  • Open Access

    Glucose metabolism and pyruvate carboxylase enhance glutathione synthesis and restrict oxidative stress in pancreatic islets

    by Accalia Fu, Lara van Rooyen, Lindsay Evans, Nina Armstrong, Daina Avizonis, Tatsuya Kin, Gregory H. Bird, Anita Reddy, Edward T. Chouchani, Marc Liesa-Roig, et al.


  • Open Access

    BAD regulates mammary gland morphogenesis by 4E-BP1-mediated control of localized translation in mouse and human models

    by John Maringa Githaka, Namita Tripathi, Raven Kirschenman, Namrata Patel, Vrajesh Pandya, David A. Kramer, Rachel Montpetit, Lin Fu Zhu, Nahum Sonenberg, Richard P. Fahlman, et al.

    Elucidation of non-canonical protein functions can identify novel tissue homeostasis pathways. Herein, we describe a role for the Bcl-2 family member BAD in postnatal mammary gland morphogenesis. InBad3SAknock-in mice, where BAD cannot undergo phosphorylation at 3 key serine residues, pubertal gland development is delayed due to aberrant tubulogenesis of the ductal epithelium. Proteomic and RPPA analyses identify that BAD regulates focal adhesions and the mRNA translation repressor, 4E-BP1. These results suggest that BAD modulates localized translation that drives focal adhesion maturation and cell motility. Consistent with this, cells withinBad3SAorganoids contain unstable protrusions with decreased compartmentalized mRNA translation and focal adhesions, and exhibit reduced cell migration and tubulogenesis. Critically, protrusion stability is rescued by 4E-BP1 depletion. Together our results confirm an unexpected role of BAD in controlling localized translation and cell migration during mammary gland development.


  • Top Cited Papers

    UCP1 governs liver extracellular succinate and inflammatory pathogenesis

    by Evanna L. Mills, Cathal Harmon, Mark P. Jedrychowski, Haopeng Xiao, Ryan Garrity, Nhien V. Tran, Gary A. Bradshaw, Accalia Fu, John Szpyt, Anita Reddy, et al.

    Non-alcoholic fatty liver disease (NAFLD), the most prevalent liver pathology worldwide, is intimately linked with obesity and type 2 diabetes. Liver inflammation is a hallmark of NAFLD and is thought to contribute to tissue fibrosis and disease pathogenesis. Uncoupling protein 1 (UCP1) is exclusively expressed in brown and beige adipocytes, and has been extensively studied for its capacity to elevate thermogenesis and reverse obesity. Here we identify an endocrine pathway regulated by UCP1 that antagonizes liver inflammation and pathology, independent of effects on obesity. We show that, without UCP1, brown and beige fat exhibit a diminished capacity to clear succinate from the circulation. Moreover, UCP1KO mice exhibit elevated extracellular succinate in liver tissue that drives inflammation through ligation of its cognate receptor succinate receptor 1 (SUCNR1) in liver-resident stellate cell and macrophage populations. Conversely, increasing brown and beige adipocyte content in mice antagonizes SUCNR1-dependent inflammatory signalling in the liver. We show that this UCP1-succinate–SUCNR1 axis is necessary to regulate liver immune cell infiltration and pathology, and systemic glucose intolerance in an obesogenic environment. As such, the therapeutic use of brown and beige adipocytes and UCP1 extends beyond thermogenesis and may be leveraged to antagonize NAFLD and SUCNR1-dependent liver inflammation.


  • CRISPR-engineered human brown-like adipocytes prevent diet-induced obesity and ameliorate metabolic syndrome in mice

    by Chih-Hao Wang, Morten Lundh, Accalia Fu, Rókus Kriszt, Tian Lian Huang, Matthew D. Lynes, Luiz O. Leiria, Farnaz Shamsi, Justin Darcy, Bennett P. Greenwood, et al.

    Human white adipocytes engineered to express UCP1 activate endogenous BAT and protect against diet-induced obesity when transplanted into mice.


  • Glucose-dependent partitioning of arginine to the urea cycle protects β-cells from inflammation

    by Accalia Fu, Juan Carlos Alvarez-Perez, Daina Avizonis, Tatsuya Kin, Scott B. Ficarro, Dong Wook Choi, Esra Karakose, Mehmet G. Badur, Lindsay Evans, Carolina Rosselot, et al.

    Chronic inflammation is linked to diverse disease processes, but the intrinsic mechanisms that determine cellular sensitivity to inflammation are incompletely understood. Here, we show the contribution of glucose metabolism to inflammation-induced changes in the survival of pancreatic islet β-cells. Using metabolomic, biochemical and functional analyses, we investigate the protective versus non-protective effects of glucose in the presence of pro-inflammatory cytokines. When protective, glucose metabolism augments anaplerotic input into the TCA cycle via pyruvate carboxylase (PC) activity, leading to increased aspartate levels. This metabolic mechanism supports the argininosuccinate shunt, which fuels ureagenesis from arginine and conversely diminishes arginine utilization for production of nitric oxide (NO), a chief mediator of inflammatory cytotoxicity. Activation of the PC–urea cycle axis is sufficient to suppress NO synthesis and shield cells from death in the context of inflammation and other stress paradigms. Overall, these studies uncover a previously unappreciated link between glucose metabolism and arginine-utilizing pathways via PC-directed ureagenesis as a protective mechanism.